Lipid-lowering therapies: A review of current and future options

James M. Backes, Daniel E. Hilleman

Research output: Contribution to specialist publicationArticle

1 Scopus citations

Abstract

Lipid-lowering therapy is used to reduce the risk of atherosclerotic cardiovascular disease (ASCVD), with statins being the drugs of choice. Despite the use of statins, the risk of additional cardiovascular events persists. Based on lipid levels and estimates of ASCVD risk, statins are used in combination with other lipid-lowering therapies, such as ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and eicosapentaenoic acid–only omega-3 fatty acids. Overall, combinations of fenofibrate or niacin with a statin have failed to reduce ASCVD risk. Potentially effective drugs with novel lipid-lowering mechanisms are currently being investigated in clinical trials for use in patients with ASCVD or familial hypercholesterolemia.

Original languageEnglish (US)
PagesHS-2-HS-11
Volume46
No2
Specialist publicationU.S. Pharmacist
StatePublished - Feb 2021

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Lipid-lowering therapies: A review of current and future options'. Together they form a unique fingerprint.

Cite this